London – Worldwide demand for the oral COVID-19 anti-viral treatment, Paxlovid manufactured by Pfizer has been unexpectedly light due to complicated eligibility requirements, reduced testing, and potential for drug interactions, a Reuters review of data and interviews with experts has found.
Demand has also been hampered by the perception that Omicron infections are not that severe.
Paxlovid was expected to be a major tool in the fight against COVID after it reduced hospitalisations or deaths in high-risk patients by around 90 per cent in a clinical trial.
Thousands of people still die from COVID-19 every week, even as global infections are far off their peak. And there are only a few proven antiviral treatments, of which Paxlovid is the most attractive. The others are the far less effective rival pill, Molnupiravir from Merck & Co. and intravenous Remdesivir from Gilead Sciences.
But even amid a recent rise in infections, Paxlovid supply far outstripped demand in the United States, United Kingdom, Japan, and South Korea, data from health ministries and Reuters interviews with doctors and pharmacists found.
“We’re just not seeing as many people coming in for testing,” Dr Timothy Hendrix, senior medical director of AdventHealth Centra Care in Florida, said.
AdventHealth Centra Care has more than 40 urgent care locations.
Hendrix said he had not prescribed Paxlovid in a few weeks. Eligible patients have turned down prescription because they believe the Omicron variant causes mild illness.
“Most of our patients (say)… ‘I’m just going to go home and tough this out’,” Hendrix said.
Pfizer plans to produce up to 120 million courses of Paxlovid this year and expects at least U.S. $22 billion in sales from contracts signed through early February.
The United States, which agreed to buy up to 20 million pills this year, making it the largest publicly known buyer, is paying around U.S. $530 a course, but prices vary by country.
Pfizer is on pace to produce 3.5 million courses earmarked for U.S. use by the end of April, the government said.
Through the first half of April, U.S. data shows it has distributed around 1.5 million courses and that pharmacies still have over 500 000 available.
“Nationally, the number of COVID-19 cases is low and so too is overall utilisation of COVID-19 therapeutics,” the Department of Health and Human Services said in a statement.
Pfizer said it initiated talks with 100 governments for Paxlovid, and agreements are in place with 26 countries.
“Governments are trying to define their demand in light of the evolving landscape with Omicron, future variants, and other antiviral options,” Pfizer said. “This is a rapidly evolving situation and changes hour by hour.”
(Reuters)